Sensitive assay for quantification of hepatitis B virus mutants by use of a minor groove binder probe and peptide nucleic acids

Journal of Clinical Microbiology

Volumn 48, Issue 12, 2010, Pages 4487-4494

  Hige, Shuhei ^a   Yamamoto, Yoichi ^a   Yoshida, Shigeru ^b   Kobayashi, Tomoe ^a   Horimoto, Hiromasa ^a   Yamamoto, Keiko ^a   Sho, Takuya ^a   Natsuizaka, Mitsuteru ^a   Nakanishi, Mitsuru ^a   Chuma, Makoto ^a   Asaka, Masahiro ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; PEPTIDE NUCLEIC ACID;

ANTIVIRAL RESISTANCE; ARTICLE; HEPATITIS B VIRUS; MINOR GROOVE BINDER PROBE; MOLECULAR PROBE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS;

ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; OLIGONUCLEOTIDE PROBES; PEPTIDE NUCLEIC ACIDS; SENSITIVITY AND SPECIFICITY;

HEPATITIS B VIRUS;

EID: 78650038247     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00731-10     Document Type: Article

References (42)

1. Afonina, I., M. Zivarts, I. Kutyavin, E. Lukhtanov, H. Gamper, and R. B. Meyer. 1997. Efficient priming of PCR with short oligonucleotides conjugated to a minor groove binder. Nucleic Acids Res. 25:2657-2660.
2. Chen, C. J., H. I. Yang, J. Su, C. L. Jen, S. L. You, S. N. Lu, G. T. Huang, U. H. Iloeje, and R.-H. S. Grp. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73.
3. Chieochansin, T., S. Chutinimitkul, S. Payungporn, A. Theamboonlers, P. Tangkijvanich, P. Komolmit, and Y. Poovorawan. 2006. Rapid detection of lamivudine-resistant hepatitis B virus mutations by PCR-based methods. Tohoku J. Exp. Med. 210:67-78.
4. Chuma, M., S. Hige, T. Kamiyama, T. Meguro, A. Nagasaka, K. Nakanishi, Y. Yamamoto, M. Nakanishi, T. Kohara, T. Sho, K. Yamamoto, H. Horimoto, T. Kobayashi, H. Yokoo, M. Matsushita, S. Todo, and M. Asaka. 2009. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J. Gastroenterol. 44:991-999.
5. Das, K., X. F. Xiong, H. L. Yang, C. E. Westland, C. S. Gibbs, S. G. Sarafianos, and E. Arnold. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 75:4771-4779.
6. de Franchis, R., G. Meucci, M. Vecchi, M. Tatarella, M. Colombo, E. Delninno, M. G. Rumi, M. F. Donato, and G. Ronchi. 1993. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann. Intern. Med. 118:191-194.
7. de Kok, J. B., E. T. G. Wiegerinck, B. A. J. Giesendorf, and D. W. Swinkels. 2002. Rapid genotyping of single nucleotide polymorphisms using novel minor groove binding DNA oligonucleotides (MGB probes). Hum. Mutat. 19:554-559.
8. Dienstag, J. L., E. R. Schiff, T. L. Wright, R. P. Perrillo, H. W. L. Hann, Z. Goodman, L. Crowther, L. D. Condreay, M. Woessner, M. Rubin, and N. A. Brown for the U.S. Lamivudine Investigator Group. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341:1256-1263.
9. Geng, H. F., B. Hua, H. Wang, Y. H. Cao, Y. Sun, and A. R. Yu. 2006. Dual-probe assay for detection of lamivudine-resistant hepatitis B virus by real-time PCR. J. Virol. Methods 132:25-31.
10. Hong, S. P., N. K. Kim, S. G. Hwang, H. J. Chung, S. Kim, J. H. Han, H. T. Kim, K. S. Rim, M. S. Kang, W. Yoo, and S. O. Kim. 2004. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J. Hepatol. 40:837-844.
11. Hua, R., Y. Tanaka, K. Fukai, M. Tada, M. Seto, Y. Asaoka, M. Ohta, T. Goto, F. Kanai, N. Kato, H. Yoshida, T. Kawabe, O. Yokosuka, and M. Omata. 2008. Rapid detection of the hepatitis B virus YMDD mutant using TaqMan-minor groove binder probes. Clin. Chim. Acta 395:151-154.
12. Hussain, M., S. Fung, E. Libbrecht, E. Sablon, C. Cursaro, P. Andreone, and A. S. F. Lok. 2006. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J. Clin. Microbiol. 44:1094-1097.
13. Jang, H., M. Cho, J. Heo, H. Kim, H. Jun, W. Shin, B. Cho, H. Park, and C. Kim. 2004. Oligonucleotide chip for detection of lamivudine-resistant hepatitis B virus. J. Clin. Microbiol. 42:4181-4188.
14. Kirishima, T., T. Okanoue, Y. Daimon, Y. Itoh, H. Nakamura, A. Morita, T. Toyama, and M. Minami. 2002. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J. Hepatol. 37:259-265. (Pubitemid 34833089)
15. Kobayashi, S., K. Shimada, H. Suzuki, K. Tanikawa, and M. Sata. 2000. Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif). Hepatol. Res. 17:31-42. (Pubitemid 30129261)
16. Kutyavin, I. V., I. A. Afonina, A. Mills, V. V. Gorn, E. A. Lukhtanov, E. S. Belousov, M. J. Singer, D. K. Walburger, S. G. Lokhov, A. A. Gall, R. Dempcy, M. W. Reed, R. B. Meyer, and J. Hedgpeth. 2000. 3′-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res. 28:655-661.
17. Lai, C. L., R. N. Chien, N. W. Y. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, P. C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, D. F. Gray, and the Asia Hepatitis Lamivudine Study Group. 1998. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:61-68.
18. Lai, C. L., J. Dienstag, E. Schiff, N. W. Y. Leung, M. Atkins, C. Hunt, N. Brown, M. Woessner, R. Boehme, and L. Condreay. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36:687-696.
19. Latorra, D., K. Campbell, A. Wolter, and J. M. Hurley. 2003. Enhanced allele-specific PCR discrimination in SNP genotyping using 3′ locked nucleic acid (LNA) primers. Hum. Mutat. 22:79-85.
20. Liaw, Y. F., J. J. Y. Sung, W. C. Chow, G. Farrell, C. Z. Lee, H. Yuen, T. Tanwandee, Q. M. Tao, K. Shue, O. N. Keene, J. S. Dixon, D. F. Gray, and J. Sabbat, for the Cirrhosis Asian Lamivudine Multicentre Study Group. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351:1521-1531.
21. Liaw, Y. F., D. I. Tai, C. M. Chu, and T. J. Chen. 1988. The development of cirrhosis patients with chronic type B hepatitis - a prospective study. Hepatology 8:493-496.
22. Libbrecht, E., J. Doutreloigne, H. Van De Velde, M. F. Yuen, C. L. Lai, F. Shapiro, and E. Sablon. 2007. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. J. Clin. Microbiol. 45:3935-3941.
23. Lok, A. S. F., C. L. Lai, N. Leung, G. B. Yao, Z. Y. Cui, E. R. Schiff, J. L. Dienstag, E. J. Heathcote, N. R. Little, D. A. Griffiths, S. D. Gardner, and M. Castiglia. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722. (Pubitemid 37500436)
24. Lole, K. S., and V. A. Arankalle. 2006. Quantitation of hepatitis B virus DNA by real-time PCR using internal amplification control and dual TaqMan MGB probes. J. Virol. Methods 135:83-90.
25. Malmstrom, S., C. Hannoun, and M. Lindh. 2007. Mutation analysis of lamivudine resistant hepatitis B virus strains by TaqMan PCR. J. Virol. Methods 143:147-152. (Pubitemid 46963385)
26. Margeridon-Thermet, S., N. S. Shulman, A. Ahmed, R. Shahriar, T. Liu, C. L. Wang, S. P. Holmes, F. Babrzadeh, B. Gharizadeh, B. Hanczaruk, B. B. Simen, M. Egholm, and R. W. Shafer. 2009. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J. Infect. Dis. 199:1275-1285.
27. Matsumoto, A., E. Tanaka, A. Rokuhara, K. Kiyosawa, H. Kumada, M. Omata, K. Okita, N. Hayashi, T. Okanoue, S. Iino, K. Tanikawa, and the Inuyama Hepatitis Study Group. 2005. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol. Res. 32:173-184.
28. Mori, K., M. Minami, T. Kirishima, K. Kunimoto, M. Okita, M. Nakayama, A. Makiyama, J. Yamaoka, T. Nakajima, K. Yasui, Y. Itoh, and T. Okanoue. 2006. Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids. Intervirology. 49:274-280.
29. Natsuizaka, M., S. Hige, Y. Ono, K. Ogawa, M. Nakanishi, M. Chuma, S. Yoshida, and M. Asaka. 2005. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region. J. Viral Hepat. 12:154-159. (Pubitemid 40342173)
30. Ohishi, W., H. Shirakawa, Y. Kawakami, S. Kimura, M. Kamiyasu, S. Tazuma, T. Nakanishi, and K. Chayama. 2004. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping. J. Med. Virol. 72:558-565.
31. Ørum, H., P. E. Nielsen, M. Egholm, R. H. Berg, O. Buchardt, and C. Stanley. 1993. Single-base pair mutation analysis by PNA directed PCR clamping. Nucleic Acids Res. 21:5332-5336.
32. Pas, S. D., S. Noppornpanth, A. A. van der Eijk, R. A. de Man, and H. G. M. Niesters. 2005. Quantification of the newly detected lamivudine resistant YSDD variants of hepatitis B virus using molecular beacons. J. Clin. Virol. 32:166-172.
33. Punia, P., P. Cane, C. G. Te, and N. Saunders. 2004. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. J. Hepatol. 40:986-992. (Pubitemid 38670133)
34. Sharon, A., and C. K. Chu. 2008. Understanding the molecular basis of HBV drug resistance by molecular modeling. Antivir. Res. 80:339-353.
35. Shaw, T., A. Bartholomeusz, and S. Locarnini. 2006. HBV drug resistance: mechanisms, detection and interpretation. J. Hepatol. 44:593-606. (Pubitemid 43227885)
36. Solmone, M., D. Vincenti, M. C. F. Prosperi, A. Bruselles, G. Ippolito, and M. R. Capobianchi. 2009. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naïve patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J. Virol. 83:1718-1726.
37. Stuyver, L., C. Van Geyt, S. De Gendt, G. Van Reybroeck, F. Zoulim, G. Leroux-Roels, and R. Rossau. 2000. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J. Clin. Microbiol. 38:702-707.
38. Sun, Z., L. F. Zhou, H. Y. Zeng, Z. Chen, and H. H. Zhu. 2007. Multiplex locked nucleic acid probes for analysis of hepatitis B virus mutants using real-time PCR. Genomics 89:151-159.
39. Tran, N., R. Berne, R. Chann, M. Gauthier, D. Martin, M. A. Armand, A. Ollivet, C. G. Teo, S. Ijaz, D. Flichman, M. Brunetto, K. P. Bielawski, C. Pichoud, F. Zoulim, and G. Vernet. 2006. European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J. Clin. Microbiol. 44:2792-2800.
40. Yoshida, S., S. Hige, M. Yoshida, N. Yamashita, S. I. Fujisawa, K. Sato, T. Kitamura, M. Nishimura, M. Chuma, M. Asaka, and H. Chiba. 2008. Quantification of lamivudine-resistant hepatitis B virus mutants by type-specific TaqMan minor groove binder probe assay in patients with chronic hepatitis B. Ann. Clin. Biochem. 45:59-64.
41. Zhao, J. R., Y. J. Bai, Q. H. Zhang, Y. Wan, D. Li, and X. J. Yan. 2005. Detection of hepatitis B virus DNA by real-time PCR using TaqMan-MGB probe technology. World J. Gastroenterol. 11:508-510.
42. Zoulim, F., and S. Locarnini. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593-1608.